Efficacy News and Research

RSS
Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Systolic, diastolic blood pressures may have different effects on different types of cardiovascular diseases

Systolic, diastolic blood pressures may have different effects on different types of cardiovascular diseases

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Research report on sports nutrition market in Europe

Research report on sports nutrition market in Europe

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Internalized stigma negatively linked with poor self-esteem and personal control of pain

Internalized stigma negatively linked with poor self-esteem and personal control of pain

New approach could lead to more effective HIV vaccine

New approach could lead to more effective HIV vaccine

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

Research shows how brain distinguishes specific voices in noisy, distracting environments

Research shows how brain distinguishes specific voices in noisy, distracting environments

Noninvasive laser therapy triggers stem cells to repair enamel of teeth

Noninvasive laser therapy triggers stem cells to repair enamel of teeth

Researchers receive $1.5M grant to lower rates of cervical cancer among incarcerated women

Researchers receive $1.5M grant to lower rates of cervical cancer among incarcerated women

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Researchers develop active agents that may improve healing of inflammatory illnesses

Researchers develop active agents that may improve healing of inflammatory illnesses

Griffith, Blackmores Institute launch special online course on complementary medicines

Griffith, Blackmores Institute launch special online course on complementary medicines

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.